---
title: "Amgen Inc. Stock Outperforms Competitors On Strong Trading Day"
type: "News"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/275175185.md"
description: "Amgen Inc. (AMGN) shares rose 4.49% to $384.32, marking a strong trading day as the S&P 500 and Dow Jones also gained. This is Amgen's third consecutive day of gains, reaching a new 52-week high, surpassing its previous peak of $374.90. Competitors like Johnson & Johnson, Pfizer, and AbbVie saw smaller increases. Trading volume was 3.8 million, above the 50-day average of 2.9 million."
datetime: "2026-02-06T21:35:35.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/275175185.md)
  - [en](https://longbridge.com/en/news/275175185.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/275175185.md)
---

> 支持的语言: [English](https://longbridge.com/en/news/275175185.md) | [繁體中文](https://longbridge.com/zh-HK/news/275175185.md)


# Amgen Inc. Stock Outperforms Competitors On Strong Trading Day

This article was automatically generated by MarketWatch using technology from Automated Insights.

Shares of Amgen Inc. (AMGN) rallied 4.49% to $384.32 Friday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index rising 1.97% to 6,932.30 and the Dow Jones Industrial Average rising 2.47% to 50,115.67.

This was the stock's third consecutive day of gains.

Amgen Inc. hit a new 52-week high, surpassing its previous peak of $374.90, which the company reached on February 5th.

The stock outperformed some of its competitors Friday, as Johnson & Johnson (JNJ) rose 0.93% to $239.99, Pfizer Inc. (PFE) rose 2.76% to $27.22, and AbbVie Inc. (ABBV) rose 2.01% to $223.43.

Trading volume (3.8 M) eclipsed its 50-day average volume of 2.9 M.

Data source: Dow Jones Market Data, FactSet. Data compiled February 6, 2026.

This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.

(END) Dow Jones Newswires

02-06-26 1635ET

### 相关股票

- [Pfizer (PFE.US)](https://longbridge.com/zh-CN/quote/PFE.US.md)
- [SPDR S&P Biotech (XBI.US)](https://longbridge.com/zh-CN/quote/XBI.US.md)
- [Direxion Daily Biotech Top 5 Bull 2X ETF (TBXU.US)](https://longbridge.com/zh-CN/quote/TBXU.US.md)
- [First Trust NYSE Arca Biotech Index Fd (FBT.US)](https://longbridge.com/zh-CN/quote/FBT.US.md)
- [Abbvie (ABBV.US)](https://longbridge.com/zh-CN/quote/ABBV.US.md)
- [Invesco Nasdaq Biotechnology ETF (IBBQ.US)](https://longbridge.com/zh-CN/quote/IBBQ.US.md)
- [iShares US Pharma (IHE.US)](https://longbridge.com/zh-CN/quote/IHE.US.md)
- [VG Health (VHT.US)](https://longbridge.com/zh-CN/quote/VHT.US.md)
- [Amgen (AMGN.US)](https://longbridge.com/zh-CN/quote/AMGN.US.md)
- [Health Care Select Sector SPDR (XLV.US)](https://longbridge.com/zh-CN/quote/XLV.US.md)
- [Proshares Ultra Nasdaq Biotech (BIB.US)](https://longbridge.com/zh-CN/quote/BIB.US.md)
- [VanEck Biotech ETF (BBH.US)](https://longbridge.com/zh-CN/quote/BBH.US.md)
- [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/zh-CN/quote/PBE.US.md)
- [iShares Global Healthcare (IXJ.US)](https://longbridge.com/zh-CN/quote/IXJ.US.md)
- [ALPS Medical Breakthrough (SBIO.US)](https://longbridge.com/zh-CN/quote/SBIO.US.md)
- [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/zh-CN/quote/IBB.US.md)
- [Ark Genomic Revolution ETF (ARKG.US)](https://longbridge.com/zh-CN/quote/ARKG.US.md)
- [Johnson & Johnson (JNJ.US)](https://longbridge.com/zh-CN/quote/JNJ.US.md)

## 相关资讯与研究

- [Pfizer Inc. Reports Positive Phase 2 Results for tilrekimig (PF-07275315) in Atopic Dermatitis](https://longbridge.com/zh-CN/news/278448836.md)
- [Johnson & Johnson Seeks Tecvayli Indication Extension in EU](https://longbridge.com/zh-CN/news/278543736.md)
- [Richard Bernstein Advisors LLC Has $1.33 Million Holdings in Pfizer Inc. $PFE](https://longbridge.com/zh-CN/news/278704455.md)
- [Pfizer’s Phase 2 Study of Trispecific Antibody Positive in Moderate to Severe Atopic Dermatitis | PFE Stock News](https://longbridge.com/zh-CN/news/278375686.md)
- [BridgeBio Pharma CEO Teases Pipeline Launches, Attruby Momentum, and Pfizer Tafamidis Trial Update](https://longbridge.com/zh-CN/news/278962353.md)